Pyxis Oncology Analyst Ratings
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology Price Target Announced at $10.00/Share by Stifel
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS) and Thermo Fisher (TMO)
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Moderna (MRNA) and Pyxis Oncology (PYXS)
Credit Suisse Reiterates Outperform on Pyxis Oncology, Maintains $14 Price Target